iBio to Present at the 24th Annual ROTH Conference on March 14
NEWARK, Del., March 7, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) will be presenting at the ROTH Capital Partners 24th Annual Conference. The conference will take place on March 11-14, 2012 in Dana Point, California.
Robert Erwin, President of iBio, will present an update on the Company's business and strategy on Wednesday, March 14 at 9:00 a.m. Investors attending the conference who would like to schedule a one-on-one meeting with Mr. Erwin should contact their ROTH Capital representative directly.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of vaccines and therapeutic proteins using transient gene expression in green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.
About ROTH Capital Partners, LLC
ROTH Capital Partners, LLC (ROTH) is a relationship-driven investment bank focused on identifying growth opportunities for corporate and institutional clients. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading and market-making services. Headquartered in Newport Beach, CA, ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S., Hong Kong and a Shanghai Representative Office. For more information on ROTH, please visit www.roth.com.
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
SOURCE iBio, Inc.